Sequence-based identification, genotyping and EUCAST antifungal susceptibilities of Trichosporon clinical isolates from Greece

Clinical Microbiology and Infection

Volumn 20, Issue 8, 2014, Pages 777-783

  Arabatzis, M ^a,b   Abel, P ^a,c   Kanellopoulou, M ^d   Adamou, D ^d   Alexandrou Athanasoulis, H ^e   Stathi, A ^e   Platsouka, E ^f   Milioni, A ^a   Pangalis, A ^e   Velegraki, A ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^c NATIONAL TECHNICAL UNIVERSITY OF ATHENS   (Greece)

^d SISMANOGLIO HOSPITAL   (Greece)

^e AGHIA SOPHIA CHILDREN S HOSPITAL   (Greece)

^f IASO GENERAL HOSPITAL   (Greece)

Author keywords

Antifungal susceptibility; D1 D2; EUCAST; Greece; intergenic spacer; MIC; Trichosporon

Indexed keywords

AMPHOTERICIN B; ANIDULAFUNGIN; ANTIFUNGAL AGENT; CASPOFUNGIN; FLUCONAZOLE; ITRACONAZOLE; MICAFUNGIN; POSACONAZOLE; RIBOSOME DNA; SPACER DNA; VORICONAZOLE; FUNGAL DNA; RIBOSOME RNA; RNA, RIBOSOMAL, 26S;

ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; CONTROLLED STUDY; FUNGAL GENE; FUNGAL STRAIN; FUNGUS ISOLATION; GENOTYPE; GREECE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SEQUENCE ANALYSIS; TREMELLALES; TRICHOSPORON; TRICHOSPORON ASAHII; TRICHOSPORON COREMIIFORME; TRICHOSPORON DERMATIS; TRICHOSPORON LOUBIERI; TRICHOSPORON MYCOTOXINIVORANS; YEAST; CHEMISTRY; CLASSIFICATION; CLUSTER ANALYSIS; DNA SEQUENCE; DRUG EFFECTS; GENETICS; HUMAN; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGICAL EXAMINATION; MOLECULAR GENETICS; MOLECULAR TYPING; PHYLOGENY;

TRICHOSPORON ASAHII; TRICHOSPORON COREMIIFORME; TRICHOSPORON DERMATIS; TRICHOSPORON LOUBIERI; TRICHOSPORON MYCOTOXINIVORANS;

ANTIFUNGAL AGENTS; CLUSTER ANALYSIS; DNA, FUNGAL; DNA, INTERGENIC; DNA, RIBOSOMAL; GENOTYPE; GREECE; HUMANS; MICROBIAL SENSITIVITY TESTS; MOLECULAR SEQUENCE DATA; MOLECULAR TYPING; MYCOLOGICAL TYPING TECHNIQUES; PHYLOGENY; RNA, RIBOSOMAL; SEQUENCE ANALYSIS, DNA; TRICHOSPORON;

EID: 84906791191     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/1469-0691.12501     Document Type: Article

References (34)

1. Colombo AL, Padovan ACB, Chaves GM. Current knowledge of Trichosporon spp. and trichosporonosis. Clin Microbiol Rev 2011; 24: 682-700.
2. Ando M, Arima K, Yoneda R, Tamura M. Japanese summer-type hypersensitivity pneumonitis: geographic distribution, home environment, and clinical characteristics of 621 cases. Am Rev Respir Dis 1991; 144: 765-769.
3. Walsh TJ, Groll AH. Emerging fungal pathogens: evolving challenges to immunocompromised patients for the twenty-first century. Transpl Infect Dis 1999; 1: 247-261.
4. Li HM, Du HT, Liu W et al. Microbiological characteristics of medically important Trichosporon species. Mycopathologia 2005; 160: 217-225.
5. Rodriguez-Tudela JL, Diaz-Guerra TM, Mellado E et al. Susceptibility patterns and molecular identification of Trichosporon species. Antimicrob Agents Chemother 2005; 49: 4026-4034.
6. Rodriguez-Tudela JL, Gomez-Lopez A, Alastruey-Izquierdo A et al. Genotype distribution of clinical isolates of Trichosporon asahii based on sequencing of intergenic spacer 1. Diagn Microbiol Infect Dis 2007; 58: 435-440.
7. Falk R, Wolf DG, Shapiro M et al. Multidrug-resistant Trichosporon asahii isolates are susceptible to voriconazole. J Clin Microbiol 2003; 41: 911.
8. Taj-Aldeen SJ, Al-Ansari N, El Shafei S et al. Molecular identification and susceptibility of Trichosporon species isolated from clinical specimens in Qatar: isolation of Trichosporon dohaense Taj-Aldeen, Meis & Boekhout sp. nov. J Clin Microbiol 2009; 47: 1791-1799.
9. Arendrup MC, Cuenca-Estrella M, Lass-Flörl C, Hope W, The EUCAST-AFST. EUCAST technical note on the EUCAST definitive document EDef 7.2: method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for yeasts EDef 7.2 (EUCAST-AFST). Clin Microbiol Infect 2012; 18: E246-E247.
10. Velegraki A, Kambouris M, Skiniotis G, Savala M, Mitroussia-Ziouva A, Legakis NJ. Identification of medically significant fungal genera with PCR followed by restriction enzyme analysis. FEMS Immunol Med Microbiol 1999; 23: 303-312.
11. Fell JW, Boekhout T, Fonseca A, Scorzetti G, Statzell-Tallman A. Biodiversity and systematics of basidiomycetous yeasts as determined by large-subunit rDNA D1/D2 domain sequence analysis. Int J Syst Evol Microbiol 2000; 50: 1351-1571.
12. Thompson JD, Higgins DG, Gibson TJ. CLUSTAL W: improving the sensitivity of progressive multiple alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res 1994; 22: 4673-4680.
13. Sugita T. Trichosporon Behrens (1890). In: Kurtzman CP, Fell JW, Boekhout T, eds, The yeasts. Amsterdam: Elsevier, 2010; 2015-2061.
14. Kimura M. A simple method for estimating evolutionary rate of base substitutions through comparative studies of nucleotide sequences. J Mol Evol 1980; 16: 111-120.
15. Tamura K, Dudley J, Nei M, Kumar S. MEGA4: molecular evolutionary genetics analysis (MEGA) software version 4.0. Mol Biol Evol 2007; 24: 1596-1599.
16. Sugita T, Nakajima M, Ikeda R, Matsushima T, Shinoda T. Sequence analysis of the ribosomal DNA Intergenic Spacer 1 regions of Trichosporon species. J Clin Microbiol 2002; 40: 1826-1830.
17. Sugita T, Ikeda R, Nishikawa A. Analysis of Trichosporon isolates obtained from the houses of patients with summer-type hypersensitivity pneumonitis. J Clin Microbiol 2004; 42: 5467-5471.
18. Kalkanci A, Sugita T, Arikan S et al. Molecular identification, genotyping, and drug susceptibility of the basidiomycetous yeast pathogen Trichosporon isolated from Turkish patients. Med Mycol 2010; 48: 141-146.
19. Clinical Laboratory Standards Institute (CLSI). Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved standard M27-A3, 3rd edn. Wayne, PA: National Committee for Clinical Laboratory Standards, 2008.
20. Guo LN, Xiao M, Kong F et al. Three-locus identification, genotyping, and antifungal susceptibilities of medically important Trichosporon species from China. J Clin Microbiol 2011; 49: 3805-3811.
21. Arendrup MC, Boekhout T, Akova M et al. ESCMID/ECMM joint clinical guideline for the diagnosis and management of rare invasive yeast infections. Clin Microbiol Infect 2013; Epub ahead of print.
22. Hickey PW, Sutton DA, Fothergill AW et al. Trichosporon mycotoxinivorans: a novel respiratory pathogen in patients with cystic fibrosis. J Clin Microbiol 2009; 47: 3091-3097.
23. Chagas-Neto TC, Chaves GM, Melo ASA, Colombo AL. Bloodstream infections due to Trichosporon spp.: species distribution, Trichosporon asahii genotypes determined on the basis of ribosomal DNA Intergenic Spacer 1 sequencing, and antifungal susceptibility testing. J Clin Microbiol 2009; 47: 1074-1081.
24. Ruan SY, Chien JY, Hsueh PR. Invasive trichosporonosis caused by Trichosporon asahii and other unusual Trichosporon species at a medical center in Taiwan. Clin Infect Dis 2009; 49: 11-17.
25. Mekha N, Sugita T, Ikeda R et al. Genotyping and antifungal drug susceptibility of the pathogenic yeast Trichosporon asahii isolated from Thai patients. Mycopathologia 2010; 169: 67-70.
26. Ribeiro MA, Alastruey-Izquierdo A, Gomez-Lopez A, Rodriguez-Tudela JL, Cuenca-Estrella M. Molecular identification and susceptibility testing of Trichosporon isolates from a Brazilian hospital. Rev Iberoam Micol 2008; 25: 221-225.
27. Antachopoulos C, Papakonstantinou E, Dotis J et al. Fungemia due to Trichosporon asahii in a neutropenic child refractory to amphotericin B. Clearance with voriconazole. J Pediatr Hematol Oncol 2005; 27: 283-285.
28. Clinical and Laboratory Standards Institute. Interpretive criteria for identification of bacteria and fungi by DNA target sequencing: guideline. CLSI document MM18-A. Wayne, PA: National Committee for Clinical Laboratory Standards, 2008.
29. Sugita T, Nishikawa A, Ikeda R, Shinoda T. Identification of medically relevant Trichosporon species based on sequences of Internal Transcribed Spacer regions and construction of a database for Trichosporon identification. J Clin Microbiol 1999; 37: 1985-1993.
30. Kolecka A, Khayhan K, Groenewald M et al. Identification of medically relevant species of arthroconidial yeasts by use of Matrix-Assisted Laser Desorption Ionization-Time of Flight mass spectrometry. J Clin Microbiol 2013; 51: 2491-2500.
31. Espinel-Ingroff A. In vitro antifungal activities of anidulafungin and micafungin, licensed agents and the investigational triazole posaconazole as determined by NCCLS methods for 12, 052 fungal isolates: review of the literature. Rev Iberoam Micol 2003; 20: 121-136.
32. Asada N, Uryu H, Koseki M, Takeuchi M, Komatsu M, Matsue K. Successful treatment of breakthrough Trichosporon asahii fungemia with voriconazole in a patient with acute myeloid leukemia. Clin Infect Dis 2006; 43: e39-e41.
33. Matsue K, Uryu H, Koseki M, Asada N, Takeuchi M. Breakthrough trichosporonosis in patients with hematologic malignancies receiving micafungin. Clin Infect Dis 2006; 42: 753-757.
34. Zaragoza O, Mesa-Arango AC, Gomez-Lopez A et al. Process analysis of variables for standardization of antifungal susceptibility testing of nonfermentative yeasts. Antimicrob Agents Chemother 2011; 55: 1563-1570.